# An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.

> **NCT03029988** · PHASE1 · TERMINATED · sponsor: **Navidea Biopharmaceuticals** · enrollment: 3 (actual)

## Conditions studied

- Liver Metastases
- Colorectal Carcinoma

## Interventions

- **DRUG:** Tilmanocept (Technetium Tc 99m tilmanocept Injection)
- **PROCEDURE:** SPECT/CT Imaging

## Key facts

- **NCT ID:** NCT03029988
- **Lead sponsor:** Navidea Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-26
- **Primary completion:** 2018-09-24
- **Final completion:** 2018-09-24
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Lack of effect in Cohort 1
- **Last updated:** 2020-09-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03029988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03029988, "An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03029988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*